MaxCyte, Inc. (MXCT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.39-4.79%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · MXCT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -0.3% |
| Our one-year growth estimate | diamond | 17.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 17.3 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 66 industry peers
MXCT — legal / regulatory event
Dated 2026-06-16
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing As previously disclosed on a Current Report on Form 8-K filed with the Securities and Exchange Commission on March 20, 2026, on March 16, 2026, MaxCyte, Inc. (the “Company”) received notice from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) that, because the closing bid price for the Company’s common stock had fallen below $1.00 per share for 30 consecutive trading…
Why it matters: The company set a year-end cash floor and remains loss-making. Its Q4 report will show whether cash stayed above that mark.
Worry ifYear-end cash, cash equivalents, and investments are at least $130.5 million.
Less concerning ifAt year-end, cash, cash equivalents, and investments are under $130.5 million.
Why it matters: The new guide is above the prior $30 million to $32 million range. Meeting it would confirm the stronger revenue outlook.
Supportive ifFinal 2026 revenue is about $34 million, with core revenue near $28 million and SPL revenue near $6 million.
Worry ifMaxCyte cuts its 2026 revenue guide below $34 million or reports 2026 revenue below $30 million.
Why it matters: Core revenue rose 26% from a year ago in the preliminary report. The final figures will test whether that growth held.
Supportive ifOn November 10, final Q3 core revenue is at least $8.1 million, close to the preliminary figure.
Worry ifOn November 10, final Q3 core revenue is under $8.1 million. Or the company reports a major drop.
Why it matters: A large customer bought instruments earlier than MaxCyte had planned. That may shift sales from Q4 into Q3.
Worry ifQ4 core revenue is at least $8.1 million, matching or topping preliminary Q3 core revenue.
Less concerning ifQ4 core revenue falls below $8.1 million. Management links the drop to the customer’s earlier instrument purchase.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$251 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $704 loss on $10,000 · 7.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,158 loss on $10,000 · 61.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.